GNPX
Price
$1.79
Change
-$0.07 (-3.76%)
Updated
Dec 26 closing price
Capitalization
4.06M
Intraday BUY SELL Signals
NERV
Price
$4.19
Change
+$0.22 (+5.54%)
Updated
Dec 26 closing price
Capitalization
181.32M
73 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

GNPX vs NERV

Header iconGNPX vs NERV Comparison
Open Charts GNPX vs NERVBanner chart's image
Genprex
Price$1.79
Change-$0.07 (-3.76%)
Volume$120.2K
Capitalization4.06M
Minerva Neurosciences
Price$4.19
Change+$0.22 (+5.54%)
Volume$54.63K
Capitalization181.32M
GNPX vs NERV Comparison Chart in %
GNPX
Daily Signal:
Gain/Loss:
NERV
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
GNPX vs. NERV commentary
Dec 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GNPX is a Hold and NERV is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 27, 2025
Stock price -- (GNPX: $1.79 vs. NERV: $4.19)
Brand notoriety: GNPX and NERV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GNPX: 24% vs. NERV: 26%
Market capitalization -- GNPX: $4.06M vs. NERV: $181.32M
GNPX [@Biotechnology] is valued at $4.06M. NERV’s [@Biotechnology] market capitalization is $181.32M. The market cap for tickers in the [@Biotechnology] industry ranges from $117.45B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GNPX’s FA Score shows that 0 FA rating(s) are green whileNERV’s FA Score has 0 green FA rating(s).

  • GNPX’s FA Score: 0 green, 5 red.
  • NERV’s FA Score: 0 green, 5 red.
According to our system of comparison, NERV is a better buy in the long-term than GNPX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GNPX’s TA Score shows that 4 TA indicator(s) are bullish while NERV’s TA Score has 5 bullish TA indicator(s).

  • GNPX’s TA Score: 4 bullish, 3 bearish.
  • NERV’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, NERV is a better buy in the short-term than GNPX.

Price Growth

GNPX (@Biotechnology) experienced а -15.96% price change this week, while NERV (@Biotechnology) price change was +3.71% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.36%. For the same industry, the average monthly price growth was +0.27%, and the average quarterly price growth was +54.56%.

Reported Earning Dates

NERV is expected to report earnings on Mar 10, 2026.

Industries' Descriptions

@Biotechnology (+0.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NERV($181M) has a higher market cap than GNPX($4.06M). NERV has higher P/E ratio than GNPX: NERV (2.57) vs GNPX (0.09). NERV YTD gains are higher at: 88.603 vs. GNPX (-95.796). NERV has higher annual earnings (EBITDA): -14.02M vs. GNPX (-16.38M). NERV has more cash in the bank: 12.3M vs. GNPX (1.1M). NERV has less debt than GNPX: NERV (0) vs GNPX (279K). GNPX (0) and NERV (0) have equivalent revenues.
GNPXNERVGNPX / NERV
Capitalization4.06M181M2%
EBITDA-16.38M-14.02M117%
Gain YTD-95.79688.603-108%
P/E Ratio0.092.573%
Revenue00-
Total Cash1.1M12.3M9%
Total Debt279K0-
FUNDAMENTALS RATINGS
GNPX vs NERV: Fundamental Ratings
GNPX
NERV
OUTLOOK RATING
1..100
7521
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
39
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9736
P/E GROWTH RATING
1..100
9899
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GNPX's Valuation (37) in the Pharmaceuticals Major industry is in the same range as NERV (39) in the Biotechnology industry. This means that GNPX’s stock grew similarly to NERV’s over the last 12 months.

GNPX's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as NERV (100) in the Biotechnology industry. This means that GNPX’s stock grew similarly to NERV’s over the last 12 months.

GNPX's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as NERV (100) in the Biotechnology industry. This means that GNPX’s stock grew similarly to NERV’s over the last 12 months.

NERV's Price Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for GNPX (97) in the Pharmaceuticals Major industry. This means that NERV’s stock grew somewhat faster than GNPX’s over the last 12 months.

GNPX's P/E Growth Rating (98) in the Pharmaceuticals Major industry is in the same range as NERV (99) in the Biotechnology industry. This means that GNPX’s stock grew similarly to NERV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GNPXNERV
RSI
ODDS (%)
Bullish Trend 1 day ago
83%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
89%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
76%
MACD
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 20 days ago
78%
Bullish Trend 9 days ago
76%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
BollingerBands
ODDS (%)
N/A
Bullish Trend 1 day ago
88%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
GNPX
Daily Signal:
Gain/Loss:
NERV
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SLRX0.660.02
+3.35%
Salarius Pharmaceuticals Inc
KWR144.551.62
+1.13%
Quaker Houghton
SNCR8.520.05
+0.59%
Synchronoss Technologies
FLOC18.01-0.01
-0.06%
Flowco Holdings Inc
FNF54.89-0.09
-0.16%
Fidelity National Financial

GNPX and

Correlation & Price change

A.I.dvisor indicates that over the last year, GNPX has been loosely correlated with NERV. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if GNPX jumps, then NERV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GNPX
1D Price
Change %
GNPX100%
-3.76%
NERV - GNPX
64%
Loosely correlated
+5.54%
TOVX - GNPX
49%
Loosely correlated
-1.70%
OMER - GNPX
48%
Loosely correlated
+2.28%
REVB - GNPX
48%
Loosely correlated
-1.14%
XERS - GNPX
31%
Poorly correlated
+2.22%
More

NERV and

Correlation & Price change

A.I.dvisor indicates that over the last year, NERV has been loosely correlated with GNPX. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if NERV jumps, then GNPX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NERV
1D Price
Change %
NERV100%
+5.54%
GNPX - NERV
64%
Loosely correlated
-3.76%
XBIO - NERV
34%
Loosely correlated
-5.45%
ACRS - NERV
33%
Loosely correlated
-0.33%
ANAB - NERV
33%
Poorly correlated
+0.18%
IDYA - NERV
32%
Poorly correlated
-1.35%
More